Abstract
Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract infections in infants and young children worldwide. Palivizumab is a humanized murine monoclonal antibody administered monthly as an intramuscular injection and significantly reduces the overall hospitalization rate due to RSV. This study evaluated the cost-utility ratio of palivizumab to prevent RSV in the Dominican Republic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
